ASCEND Phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) (2158)
Wojciech Jurczak
Click the following button to download this presentation’s slides
2019 Presentations Access
Thank you for your interest in viewing the iwCLL 2019 video presentations.
Please complete the following information below to access the presentations.